Serum hepcidin predicts uremic accelerated atherosclerosis in chronic hemodialysis patients with diabetic nephropathy

Chinese Medical Journal

Volumn 128, Issue 10, 2015, Pages 1351-1357

  Li, Han ^a   Feng, Su Juan ^a   Su, Lu Lu ^a   Wang, Wei ^a   Zhang, Xiao Dong ^a   Wang, Shi Xiang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Hemodialysis; Hepcidin; Iron Status

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; FERRITIN; HEPCIDIN; INTERLEUKIN 6; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PROTEIN; TRANSFERRIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTHROPOMETRY; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CAROTID ARTERY ULTRASONOGRAPHY; CHRONIC GLOMERULONEPHRITIS; CLINICAL ASSESSMENT; DEMOGRAPHY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RISK FACTOR; STATISTICAL ANALYSIS; UREMIC ACCELERATED ATHEROSCLEROSIS; AGED; BLOOD; DIABETIC NEPHROPATHIES; RENAL REPLACEMENT THERAPY; YOUNG ADULT;

ADULT; AGED; ATHEROSCLEROSIS; DIABETIC NEPHROPATHIES; FEMALE; HEPCIDINS; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; YOUNG ADULT;

EID: 84929154297     PISSN: 03666999     EISSN: 25425641     Source Type: Journal    
DOI: 10.4103/0366-6999.156781     Document Type: Article

References (46)

1. González FF. Results of the explicit health guaranties program to correct anemia of end stage renal disease patients in dialysis. Rev Med Chil 2013;141:568-73.
2. De Nicola L, Minutolo R, Chiodini P, Zamboli P, Cianciaruso B, Nappi F, et al. Prevalence and prognosis of mild anemia in non-dialysis chronic kidney disease: A prospective cohort study in outpatient renal clinics. Am J Nephrol 2010;32:533-40.
3. Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice position statement. Nephrol Dial Transplant 2013;28:1346-59.
4. Onken JE, Bregman DB, Harrington RA, Morris D, Buerkert J, Hamerski D, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: The REPAIR-IDA trial. Nephrol Dial Transplant 2014;29:833-42.
5. Majoni SW, Ellis JA, Hall H, Abeyaratne A, Lawton PD. Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia. Hemodial Int 2014;18:740-50.
6. Hukic F, Nuhbegovic S, Brkic S, Ostrvica E, Custendil-Delic S, Mustafic S. Biochemical markers of iron status in hemodialysis patients. Med Arh 2010;64:219-22.
7. Bratescu LO, Bârsan L, Gârneata L, Stanciu A, Lipan M, Stancu SH, et al. Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency. Int Urol Nephrol 2014;46:1005-12.
8. Sarnak MJ, Foley RN. Cardiovascular mortality in the general population versus dialysis: A glass half full or empty? Am J Kidney Dis 2011;58:4-6.
9. Yadav AK, Banerjee D, Lal A, Jha V. Vitamin D deficiency, CD4+CD28null cells and accelerated atherosclerosis in chronic kidney disease. Nephrology (Carlton) 2012;17:575-81.
10. Koc Y, Unsal A, Kayabasi H, Oztekin E, Sakaci T, Ahbap E, et al. Impact of volume status on blood pressure and left ventricle structure in patients undergoing chronic hemodialysis. Ren Fail 2011;33:377-81.
11. Verbeke F, Van Biesen W, Honkanen E, Wikström B, Jensen PB, Krzesinski JM, et al. Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: Outcome of the calcification outcome in renal disease (CORD) study. Clin J Am Soc Nephrol 2011;6:153-9.
12. Li H, Wang SX. Improvement of hypertension and LVH in maintenance hemodialysis patients treated with sustained-release isosorbide mononitrate. J Nephrol 2011;24:236-45.
13. Valenti L, Swinkels DW, Burdick L, Dongiovanni P, Tjalsma H, Motta BM, et al. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2011;21:568-75.
14. Valenti L, Dongiovanni P, Motta BM, Swinkels DW, Bonara P, Rametta R, et al. Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol 2011;31:683-90.
15. van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant 2013;28:3062-71.
16. Martinelli N, Traglia M, Campostrini N, Biino G, Corbella M, Sala C, et al. Increased serum hepcidin levels in subjects with the metabolic syndrome: A population study. PLoS One 2012;7:e48250.
17. Kuragano T, Itoh K, Shimonaka Y, Kida A, Furuta M, Kitamura R, et al. Hepcidin as well as TNF-a are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial Transplant 2011;26:2663-7.
18. van den Munckhof I, Scholten R, Cable NT, Hopman MT, Green DJ, Thijssen DH. Impact of age and sex on carotid and peripheral arterial wall thickness in humans. Acta Physiol (Oxf) 2012;206:220-8.
19. Bosevski M. Carotid IMT in type 2 diabetic patients: a survey on factors of influence. Prilozi 2011;32:289-97.
20. Tahir MA, Dmitrieva O, de Lusignan S, van Vlymen J, Chan T, Golmohamad R, et al. Confidence and quality in managing CKD compared with other cardiovascular diseases and diabetes mellitus: A linked study of questionnaire and routine primary care data. BMC Fam Pract 2011;12:83.
21. Bakris G, Vassalotti J, Ritz E, Wanner C, Stergiou G, Molitch M, et al. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: An integrated therapeutic approach to reduce events. Kidney Int 2010;78:726-36.
22. Mejía-Rodríguez O, Herrera-Abarca JE, Ceballos-Reyes G, Avila-Diaz M, Prado-Uribe C, Belio-Caro F, et al. Cardiovascular and renal effects of bromocriptine in diabetic patients with stage 4 chronic kidney disease. Biomed Res Int 2013;2013:104059.
23. Ohsawa M, Tanno K, Itai K, Turin TC, Okamura T, Ogawa A, et al. Comparison of predictability of future cardiovascular events between chronic kidney disease (CKD) stage based on CKD epidemiology collaboration equation and that based on modification of diet in renal disease equation in the Japanese general population – Iwate KENCO Study. Circ J 2013;77:1315-25.
24. Marinelli A, Orlandi L, Stivali G. C-reactive protein levels are associated with arterial media calcification in nondiabetic patients with end-stage renal disease on long-term hemodialysis. Clin Nephrol 2011;76:425-34.
25. Stróżecki P, Donderski R, Kardymowicz A, Manitius J. Comparison of arterial stiffness in end-stage renal disease patients treated with peritoneal dialysis or hemodialysis. Pol Arch Med Wewn 2012;122:33-9.
26. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697-701.
27. Muntner P, He J, Astor BC, Folsom AR, Coresh J.: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005;16:529-38.
28. Smink PA, Lambers Heerspink HJ, Gansevoort RT, de Jong PE, Hillege HL, Bakker SJ, et al. Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: The PREVEND (Prevention of Renal and Vascular Endstage Disease) study. Am J Kidney Dis 2012;60:804-11.
29. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, et al. ‘United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 2012;59:A7, e1-420.
30. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: Effects on the cardiovascular system. Circulation 2007;116:85-97.
31. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3.
32. Canavesi E, Alfieri C, Pelusi S, Valenti L. Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease. World J Nephrol 2012;1:166-76.
33. Maliken BD, Nelson JE, Kowdley KV. The hepcidin circuits act: Balancing iron and inflammation. Hepatology 2011;53:1764-6.
34. De Domenico I, Zhang TY, Koening CL, Branch RW, London N, Lo E, et al. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest 2010;120:2395-405.
35. KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530.
36. Vaziri ND. Toxic effects of IV iron preparations in CKD patients. Nephrol News Issues 2014;28:4-5.
37. Ng JM, Cooke M, Bhandari S, Atkin SL, Kilpatrick ES. The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease. Diabetes Care 2010;33:2310-3.
38. Belcaro G, Nicolaides AN, Laurora G, Cesarone MR, De Sanctis M, Incandela L, et al. Ultrasound morphology classification of the arterial wall and cardiovascular events in a 6-year follow-up study. Arterioscler Thromb Vasc Biol 1996;16:851-6.
39. Jadhav UM, Kadam NN.: Apolipoproteins: Correlation with carotid intimamedia thickness and coronary artery disease. J Assoc Physicians India 2004;52:370-5.
40. Llisterri JL, Barrios V, de la Sierra A, Bertomeu V, Escobar C, González-Segura D. Blood pressure control in hypertensive women aged 65 years or older in a primary care setting. MERICAP study. Rev Esp Cardiol 2011;64:654-A60.
41. Shah SV, Alam MG. Role of iron in atherosclerosis. Am J Kidney Dis 2003;41:S80-3.
42. Van Lenten BJ, Prieve J, Navab M, Hama S, Lusis AJ, Fogelman AM. Lipid-induced changes in intracellular iron homeostasis in vitro and in vivo. J Clin Invest 1995;95:2104-10.
43. Matthews AJ, Vercellotti GM, Menchaca HJ, Bloch PH, Michalek VN, Marker PH, et al. Iron and atherosclerosis: Inhibition by the iron chelator deferiprone (L1). J Surg Res 1997;73:35-40.
44. Porreca E, Ucchino S, Di Febbo C, Di Bartolomeo N, Angelucci D, Napolitano AM, et al. Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo. Arterioscler Thromb 1994;14:299-304.
45. Reis KA, Guz G, Ozdemir H, Erten Y, Atalay V, Bicik Z, et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J 2005;46:255-64.
46. Stadler N, Lindner RA, Davies MJ.: Direct detection and quantification of transition metal ions in human atherosclerotic plaques: Evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 2004;24:949-54.